Addison Skigen

Articles

Grifols, S.A., is collaborating with federal health agencies on a development process for a COVID-19 treatment therapy in the company's Clayton facility. The company is ready to begin collecting convalescent plasma from the blood of recovered individuals and manufacturing it into an immune globulin that they hope will help combat the virus following infection; however questions of its affordability remain. Photo courtesy of Grifols.

A COVID-19 treatment may be developed in N.C., but the therapy's cost remains uncertain

A potential treatment for COVID-19 could being development just outside the Research Triangle Park in Clayton, North Carolina. The Spanish pharmaceutical company Grifols, S.A. is spearheading a project with U.S. government assistance from the Food and Drug Administration and the Biomedical Advanced Research Development Authority.  As of Monday, the company is ready to begin collecting convalescent plasma from the blood of recovered individuals and will work towards manufacturing it into an immune globulin that they hope will help combat the virus following infection. Once developed, it's possible the price of this treatment could be very high and whether the federal government will help establish affordability remains unclear.